Abstract
ObjectiveHigher blood malondialdehyde (biomarker of lipid peroxidation) levels in the first hours of traumatic brain injury (TBI) have been found in patients with a worst prognosis. The objective of this study was to determine whether serum malondialdehyde levels during the first week of severe TBI could be used as mortality biomarkers. This was a multicenter, prospective and observational study performed in six Spanish Intensive Care Units. We included patients with severe TBI (defined as Glasgow Coma Scale < 9), and with Injury Severity Score in non-cranial aspects < 9. We determined serum malondialdehyde concentrations at days 1, 4 and 8 of TBI. We stablished 30-day mortality as the end-point study.ResultsWe found that serum malondialdehyde concentrations at days 1 (p < 0.001), 4 (p < 0.001), and 8 (p < 0.001) of TBI were higher in non-survivor (n = 34) than in survivor (n = 90) patients. We found an area under curve of serum malondialdehyde concentrations at days 1, 4, and 8 of TBI to predict 30-day mortality of 77% (p < 0.001), 87% (p < 0.001) and 84% (p < 0.001) respectively. Thus, the new and most relevant findings of our study were serum malondialdehyde levels during the first week of TBI could be used as mortality biomarkers.
Highlights
Traumatic brain injury (TBI) leads to many deaths, and to many disabilities and consumption of resources [1]
We found an area under curve of serum malondialdehyde concentrations at days 1, 4, and 8 of TBI to predict 30-day mortality of 77% (p < 0.001), 87% (p < 0.001) and 84% (p < 0.001) respectively
We found that non-survivor in respect to survivor patients showed higher serum malondialdehyde concentrations at days 1 (p < 0.001), 4 (p < 0.001), and 8 (p < 0.001) of TBI (Fig. 1)
Summary
Traumatic brain injury (TBI) leads to many deaths, and to many disabilities and consumption of resources [1]. In TBI could appears a secondary brain injury during the following hours or days after TBI due to the neuroinflammatory response and the generation of free radicals [2–5]. In TBI appears an increase in the production of ROS and this leads to lipid peroxidation. Previous studies have reported higher blood levels of malondialdehyde in TBI patients than in controls subjects [8–15]. Higher blood malondialdehyde levels in the first hours of TBI in patients with a worst prognosis have been found [13–16]. The objective of this study was to determine serum malondialdehyde levels during the first week of a severe TBI and to analyze whether those levels during the first week are difference between survivor and non-survivor patients, and whether could be used as biomarkers of mortality
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
